Wucherpfennig Lab Publications

Regulation of the immune CD155-CD226-TIGIT axis by cyclin D-CDK4/6. Proc Natl Acad Sci U S A. 2026 Mar 24;123(12):e2522872123. 

Multimodal framework for the joint analysis of single-cell RNA and T cell receptor sequencing data predicts T cell response to cancer immunotherapy. Nat Commun. 2026 Mar 12. doi: 10.1038/s41467-026-70505-0. 

Persistent T cell activation and cytotoxicity against glioblastoma following single oncolytic virus treatment in a clinical trial. Cell. 2026 Mar 5;189(5):1287-1304.e18

CRATER tumor niches facilitate CD8⁺ T cell engagement and correspond with immunotherapy success. Cell. 2025 Nov 26;188(24):6720-6736.e26. doi: 10.1016/j.cell.2025.09.021. 

Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities. Clin Cancer Res. 2025 Oct 1;31(19):4122-4135. doi: 10.1158/1078-0432.CCR-25-0512.

Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma. Cancer Cell. 2025 Jun 9;43(6):1175-1176. doi: 10.1016/j.ccell.2025.05.007. Epub 2025 May 27.

Dissecting the immune landscape in pediatric high-grade glioma reveals cell state changes under therapeutic pressure. Cell Rep Med. 2025 May 20; 6(5):102095. 

Unlocking LAG3: Ubiquitin's unexpected role. Cell. 2025 May 01; 188(9):2307-2309.  

Integrated computational analysis identifies therapeutic targets with dual action in cancer cells and T cells. Immunity. 2025 Mar 11; 58(3):745-765.e9.  

Selective deficiency of mitochondrial respiratory complex I subunits Ndufs4/6 causes tumor immunogenicity. Nat Cancer. 2025 Feb; 6(2):323-337. 

Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma. Clin Cancer Res. 2025 Jan 17; 31(2):316-327. 

Defective removal of invariant chain peptides from MHC class II suppresses tumor antigen presentation and promotes tumor growth. Cell Rep. 2025 01 28; 44(1):115150. 

Tissue-Resident T Cells in Clinical Response and Immune-Related Adverse Events of Immune Checkpoint Blockade. Clin Cancer Res. 2024 Dec 16; 30(24):5527-5534.

Inhibition of MICA and MICB shedding enhances memory-like NK-cell-mediated cytotoxicity against multiple myeloma. Blood Adv. 2024 10 22; 8(20):5365-5370.

A CAR enhancer increases the activity and persistence of CAR T cells. Nat Biotechnol. 2024 Jul 30. 

Author Correction: Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments. Nat Cell Biol. 2024 May; 26(5):841. 

Targeting of the CD161 inhibitory receptor enhances T-cell-mediated immunity against hematological malignancies. Blood. 2024 03 21; 143(12):1124-1138.

MICA-specific nanobodies for diagnosis and immunotherapy of MICA⁺ tumors. Front Immunol. 2024 Mar 14;15:1368586. doi: 10.3389/fimmu.2024.1368586. eCollection 2024.

Neoadjuvant immune checkpoint blockade enhances local and systemic tumor immunity in head and neck cancer. Curr Opin Oncol. 2024 May 01; 36(3):136-142. 

Heterogeneity and transcriptional drivers of triple-negative breast cancer. Cell Rep. 2023 12 26; 42(12):113564. 

Transforming ovarian cancer care by targeting minimal residual disease. Med. 2023 11 10; 4(11):755-760. 

Clinical trial links oncolytic immunoactivation to survival in glioblastoma. Nature. 2023 Nov; 623(7985):157-166. 

Selective Mitochondrial Respiratory Complex I Subunit Deficiency Causes Tumor Immunogenicity. bioRxiv. 2023 Oct 03. 

The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity. Cancer Cell. 2023 07 10; 41(7):1207-1221.e12. 

Injectable Oxygen Microparticles Boost Radiation-Mediated In Situ Vaccination and Systemic Antitumor Immune Responses. Int J Radiat Oncol Biol Phys. 2023 Jul 15; 116(4):906-915. 

A chimeric antigen receptor uniquely recognizing MICA/B stress proteins provides an effective approach to target solid tumors. Med. 2023 Jul 14; 4(7):457-477.e8. 

Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell-Secreted Cytokines. Cancer Discov. 2023 05 04; 13(5):1186-1209. 

Systematic Interrogation of Tumor Cell Resistance to Chimeric Antigen Receptor T-cell Therapy in Pancreatic Cancer. Cancer Res. 2023 02 15; 83(4):613-625. 

A structural platform for B cell receptor signaling. Cell Res. 2023 02; 33(2):95-96. 

Cytokine conjugation to enhance T cell therapy. Proc Natl Acad Sci U S A. 2023 01 03; 120(1):e2213222120. 

Designing Cancer Immunotherapies That Engage T Cells and NK Cells. Annu Rev Immunol. 2023 04 26; 41:17-38. 

Breast cancer prevention by short-term inhibition of TGFß signaling. Nat Commun. 2022 12 07; 13(1):7558. 

Oncometabolite d-2HG alters T cell metabolism to impair CD8+ T cell function. Science. 2022 09 30; 377(6614):1519-1529. 

Mechanical checkpoint regulates monocyte differentiation in fibrotic niches. Nat Mater. 2022 08; 21(8):939-950. 

Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy. Cell. 2022 08 04; 185(16):2918-2935.e29. 

A vaccine targeting resistant tumours by dual T cell plus NK cell attack. Nature. 2022 06; 606(7916):992-998. 

MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets. Nat Commun. 2022 05 13; 13(1):2559. 

A Conceptual Framework for Inducing T Cell-Mediated Immunity Against Glioblastoma. Semin Immunopathol. 2022 09; 44(5):697-707. 

Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis. Cell. 2022 04 28; 185(9):1521-1538.e18. 

Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche. Cell. 2022 05 12; 185(10):1694-1708.e19. 

MICA/B-targeted antibody promotes NK cell-driven tumor immunity in patients with intrahepatic cholangiocarcinoma. Oncoimmunology. 2022; 11(1):2035919. 

MICA/B antibody induces macrophage-mediated immunity against acute myeloid leukemia. Blood. 2022 01 13; 139(2):205-216. 

Systematic investigation of cytokine signaling activity at the tissue and single-cell levels. Nat Methods. 2021 10; 18(10):1181-1191. 

Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma. Cancer Cell. 2021 06 14; 39(6):779-792.e11. 

cIAP1/2 antagonism eliminates MHC class I-negative tumors through T cell-dependent reprogramming of mononuclear phagocytes. Sci Transl Med. 2021 05 19; 13(594). 

Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation. Cancer Discov. 2021 10; 11(10):2564-2581. 

CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells. Cancer Discov. 2021 08; 11(8):2050-2071. 

Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell. 2021 03 18; 184(6):1575-1588. 

Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion. Nat Genet. 2021 03; 53(3):332-341. 

Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell. 2021 03 04; 184(5):1281-1298.e26. 

Immunosuppressive Myeloid Cells Induce Nitric Oxide-Dependent DNA Damage and p53 Pathway Activation in CD8+ T Cells. Cancer Immunol Res. 2021 04; 9(4):470-485. 

Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma. Nat Med. 2021 02; 27(2):289-300. 

Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat Med. 2021 03; 27(3):515-525. 

Integrin avß6-TGFß-SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast Cancer. Cancer Cell. 2021 01 11; 39(1):54-67.e9. 

Mechanism of EBV inducing anti-tumour immunity and its therapeutic use. Nature. 2021 02; 590(7844):157-162. 

Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. JAMA Oncol. 2020 10 01; 6(10):1563-1570. 

Inhibition of MAN2A1 Enhances the Immune Response to Anti-PD-L1 in Human Tumors. Clin Cancer Res. 2020 11 15; 26(22):5990-6002. 

Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric Ependymoma. Cancer Cell. 2020 07 13; 38(1):44-59.e9. 

Correction: Hdac3 is an epigenetic inhibitor of the cytotoxicity program in CD8 T cells. J Exp Med. 2020 07 06; 217(7). 

Hdac3 is an epigenetic inhibitor of the cytotoxicity program in CD8 T cells. J Exp Med. 2020 07 06; 217(7). 

Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. Cell. 2020 08 06; 182(3):655-671.e22. 

Metabolic labeling and targeted modulation of dendritic cells. Nat Mater. 2020 11; 19(11):1244-1252. 

Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. Mol Cell. 2020 06 18; 78(6):1096-1113.e8. 

Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer. Nat Commun. 2020 05 11; 11(1):2350. 

Inhibition of MICA and MICB Shedding Elicits NK-Cell-Mediated Immunity against Tumors Resistant to Cytotoxic T Cells. Cancer Immunol Res. 2020 06; 8(6):769-780. 

Distinct Mesenchymal Cell Populations Generate the Essential Intestinal BMP Signaling Gradient. Cell Stem Cell. 2020 03 05; 26(3):391-402.e5. 

Ascl2-Dependent Cell Dedifferentiation Drives Regeneration of Ablated Intestinal Stem Cells. Cell Stem Cell. 2020 03 05; 26(3):377-390.e6. 

Replicational Dilution of H3K27me3 in Mammalian Cells and the Role of Poised Promoters. Mol Cell. 2020 04 02; 78(1):141-151.e5. 

Inhibition of Haspin Kinase Promotes Cell-Intrinsic and Extrinsic Antitumor Activity. Cancer Res. 2020 02 15; 80(4):798-810. 

Discovery of specialized NK cell populations infiltrating human melanoma metastases. JCI Insight. 2019 12 05; 4(23). 

MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature. 2019 10; 574(7780):696-701. 

T-Scan: A Genome-wide Method for the Systematic Discovery of T Cell Epitopes. Cell. 2019 08 08; 178(4):1016-1028.e13. 

Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments. Nat Cell Biol. 2019 07; 21(7):879-888. 

Publisher Correction: Landscape of B cell immunity and related immune evasion in human cancers. Nat Genet. 2019 Jun; 51(6):1068. 

Visualization and quantification of NK cell-mediated cytotoxicity over extended time periods by image cytometry. J Immunol Methods. 2019 06; 469:47-51. 

Epithelial endoplasmic reticulum stress orchestrates a protective IgA response. Science. 2019 03 01; 363(6430):993-998. 

Landscape of B cell immunity and related immune evasion in human cancers. Nat Genet. 2019 03; 51(3):560-567. 

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019 01; 565(7738):234-239. 

Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med. 2018 12; 24(12):1845-1851. 

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 2018 11 01; 175(4):984-997.e24. 

FAP Delineates Heterogeneous and Functionally Divergent Stromal Cells in Immune-Excluded Breast Tumors. Cancer Immunol Res. 2018 12; 6(12):1472-1485. 

Rapid CLIP dissociation from MHC II promotes an unusual antigen presentation pathway in autoimmunity. J Exp Med. 2018 10 01; 215(10):2617-2635. 

Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018 10; 24(10):1550-1558. 

Engineered MBP-specific human Tregs ameliorate MOG-induced EAE through IL-2-triggered inhibition of effector T cells. J Autoimmun. 2018 08; 92:77-86. 

Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses. Nat Commun. 2018 05 14; 9(1):1884. 

Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science. 2018 04 20; 360(6386):331-335. 

Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity. Science. 2018 Mar 30; 359(6383):1537-1542. 

Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2018 03 14; 555(7696):402. 

A facile approach to enhance antigen response for personalized cancer vaccination. Nat Mater. 2018 06; 17(6):528-534. 

Signaling by the Epstein-Barr virus LMP1 protein induces potent cytotoxic CD4+ and CD8+ T cell responses. Proc Natl Acad Sci U S A. 2018 01 23; 115(4):E686-E695. 

A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science. 2018 02 16; 359(6377):770-775. 

T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity. Nat Commun. 2017 11 23; 8(1):1747. 

Immunotherapy for glioblastoma: on the sidelines or in the game? Discov Med. 2017 11; 24(133):201-208. 

Erratum: The microRNA miR-31 inhibits CD8+ T cell function in chronic viral infection. Nat Immunol. 2017 09 19; 18(10):1173. 

Immunomodulation for glioblastoma. Curr Opin Neurol. 2017 06; 30(3):361-369. 

The microRNA miR-31 inhibits CD8+ T cell function in chronic viral infection. Nat Immunol. 2017 Jul; 18(7):791-799. 

Noninvasive Imaging of Human Immune Responses in a Human Xenograft Model of Graft-Versus-Host Disease. J Nucl Med. 2017 06; 58(6):1003-1008. 

Multicomponent Injectable Hydrogels for Antigen-Specific Tolerogenic Immune Modulation. Adv Healthc Mater. 2017 Mar; 6(6). 

Studying Dynamic Plasma Membrane Binding of TCR-CD3 Chains During Immunological Synapse Formation Using Donor-Quenching FRET and FLIM-FRET. Methods Mol Biol. 2017; 1584:259-289. 

Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors. Cancer Immunol Res. 2016 12; 4(12):1038-1048. 

Binding of the cytoplasmic domain of CD28 to the plasma membrane inhibits Lck recruitment and signaling. Sci Signal. 2016 07 26; 9(438):ra75. 

Genetic screens to study the immune system in cancer. Curr Opin Immunol. 2016 08; 41:55-61. 

Clinical and MRI phenotype of children with MOG antibodies. Mult Scler. 2016 Feb; 22(2):174-84.